ADAR1 Capital Management »

Argenx Se shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Argenx Se (ARGX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Argenx Se

Tip: Access up to 7 years of quarterly data

All positions including Argenx Se held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Argenx Se by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $27k 70 380.43

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Argenx Se

T. Rowe Price Associates
Artisan Partners Limited Partnership
Henderson Group
venBio Select Advisor
Bellevue Group
Massachusetts Financial Services
Holocene Advisors
Millennium Management
ClearBridge Advisors
Paradigm Biocapital Advisors
Federated Investors
Citadel Advisors
Sei Investments
EcoR1 Capital
Bamco

View all funds holding Argenx Se